Results
Ipca Labs Q4 FY26 EBITDA Margin Expands to 25.3%
Ipca Laboratories reported Q4 FY26 stand-alone EBITDA margin of 25.27%, a 408 basis point improvement year-over-year.
Consolidated revenue grew 8% to ₹9,646 crore in FY26 with domestic formulations gr
